

**Listing of Claims**

1-8. (canceled)

9. (previously presented) A method of inhibiting or neutralizing WISP-1 induction or secretion of HAS2, HA, CD44 or RHAMM in mammalian cells, comprising exposing said mammalian cells to an effective amount of WISP-1 antagonist, wherein said WISP-1 antagonist comprises the 3D11, 11C2, 9C10, 5D4, or 9C11 monoclonal antibody secreted by the hybridoma deposited with ATCC as accession number PTA-4624, PTA-4628, PTA-4626, PTA-4625, or PTA-4627, respectively.

10-12. (canceled)

13. (original) The method of claim 9, wherein said mammalian cells comprise cancer cells.

14. (currently amended) The method of claim 13, wherein said mammalian cells comprise pancreatic cancer cells, colon or colorectal cancer cells, breast cancer cells, lung cancer cells or brain cancer cells.

15-30. (canceled)

31. (previously presented) The method of claim 9, wherein said monoclonal antibody is linked to one or more agents selected from the group consisting of non-proteinaceous polymer, cytotoxic agent, enzyme, radioisotope, fluorescent compound, and chemiluminescent compound.

32. (previously presented) A method of inhibiting or neutralizing WISP-1 induction or secretion of HAS2, HA, CD44 or RHAMM in mammalian cells, comprising exposing said mammalian cells to an effective amount of WISP-1 antagonist, wherein said WISP-1 antagonist comprises an anti-WISP-1 monoclonal antibody which binds to the same epitope as the epitope to which the 3D11, 11C2, 9C10, 5D4, or 9C11 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number PTA-4624, PTA-4628, PTA-4626, PTA-4625, or PTA-4627, respectively, binds.

33. (previously presented) The method of claim 32, wherein said anti-WISP-1 monoclonal antibody is linked to one or more agents selected from the group consisting of non-proteinaceous polymer, cytotoxic agent, enzyme, radioisotope, fluorescent compound, and chemiluminescent compound.

34. (previously presented) The method of claim 32, wherein said mammalian cells comprise cancer cells.

35. (currently amended) The method of claim 34, wherein said mammalian cells comprise pancreatic cancer cells, colon or colorectal cancer cells, breast cancer cells, lung cancer cells or brain cancer cells.

36. (currently amended) A method of inhibiting or neutralizing WISP-1 induction or secretion of HAS2, HA, CD44 or RHAMM in mammalian cells, comprising exposing said mammalian cells to an effective amount of WISP-1 antagonist, wherein said WISP-1 antagonist comprises a chimeric anti-WISP-1 antibody which specifically binds to WISP-1 polypeptide, and wherein said chimeric anti-WISP-1 antibody ~~and~~ comprises a ~~sequence derived~~ fragment from the 3D11, 11C2, 9C10, 5D4, or 9C11 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number PTA-4624, PTA-4628, PTA-4626, PTA-4625, or PTA-4627, respectively, which specifically binds to WISP-1 polypeptide.

37. (currently amended) The method of claim 36, wherein said ~~derived sequence fragment~~ is the variable or hypervariable region of the 3D11, 11C2, 9C10, 5D4, or 9C11 monoclonal antibody.

38. (previously presented) The method of claim 36, wherein said chimeric anti-WISP-1 antibody is a humanized antibody.

39. (previously presented) The method of claim 36, wherein said mammalian cells comprise cancer cells.

40. (currently amended) The method of claim 36, wherein said mammalian cells comprise pancreatic cancer cells, colon or colorectal cancer cells, breast cancer cells, lung cancer cells or brain cancer cells.

41. (previously presented) The method of claim 36, wherein said chimeric anti-WISP-1 antibody is linked to one or more agents selected from the group consisting of non-proteinaceous polymer, cytotoxic agent, enzyme, radioisotope, fluorescent compound, and chemiluminescent compound.

42. (new) The method of claim 32, wherein said antibody is a chimeric, human, or humanized antibody.

43. (new) A monoclonal antibody comprising the 3D11, 11C2, 9C10, 5D4, or 9C11 antibody secreted by the hybridoma deposited with ATCC as accession number PTA-4624, PTA-4628, PTA-4626, PTA-4625, or PTA-4627, respectively.

44. (new) The monoclonal antibody of claim 43, wherein said antibody is linked to one or more agents selected from the group consisting of non-proteinaceous polymer, cytotoxic agent, enzyme, radioisotope, fluorescent compound, and chemiluminescent compound.

45. (new) An isolated WISP-1 antagonist comprising an anti-WISP-1 antibody which binds to the same epitope as the epitope to which the 3D11, 11C2, 9C10, 5D4, or 9C11 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number PTA-4624, PTA-4628, PTA-4626, PTA-4625, or PTA-4627, respectively, binds.

46. (new) The antagonist of claim 45, wherein said anti-WISP-1 antibody is a chimeric, human, or humanized antibody.

47. (new) The antagonist of claim 45, wherein said anti-WISP-1 antibody is a humanized antibody.

48. (new) The antagonist of claim 45, wherein said anti-WISP-1 antibody is linked to one or more agents selected from the group consisting of non-proteinaceous polymer, cytotoxic agent, enzyme, radioisotope, fluorescent compound, and chemiluminescent compound.

49. (new) An isolated WISP-1 antagonist comprising an anti-WISP-1 antibody which binds to WISP-1 polypeptide and competitively inhibits binding of the monoclonal antibody 3D11, 11C2, 9C10, 5D4, or 9C11 produced by the hybridoma cell line deposited as ATCC accession number PTA-4624, PTA-4628, PTA-4626, PTA-4625, or PTA-4627, respectively, to said WISP-1 polypeptide.

50. (new) The antagonist of claim 49, wherein said anti-WISP-1 antibody is a chimeric, human, or humanized antibody.

51. (new) The antagonist of claim 49, wherein said anti-WISP-1 antibody is a humanized antibody.

52. (new) The antagonist of claim 49, wherein said anti-WISP-1 antibody is linked to one or more agents selected from the group consisting of non-proteinaceous polymer, cytotoxic agent, enzyme, radioisotope, fluorescent compound, and chemiluminescent compound.

53. (new) An isolated WISP-1 antagonist comprising a chimeric anti-WISP-1 antibody which specifically binds to WISP-1 polypeptide wherein said antibody comprises a fragment from the 3D11, 11C2, 9C10, 5D4, or 9C11 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number PTA-4624, PTA-4628, PTA-4626, PTA-4625, or PTA-4627, respectively, which specifically binds to WISP-1 polypeptide.

54. (new) The antagonist of claim 53, wherein said fragment is the variable or hypervariable region of the 3D11, 11C2, 9C10, 5D4, or 9C11 monoclonal antibody.

55. (new) The antagonist of claim 53, wherein said anti-WISP-1 antibody is a chimeric, human, or humanized antibody.

56. (new) The antagonist of claim 53, wherein said anti-WISP-1 antibody is a humanized antibody.

57. (new) The antagonist of claim 53, wherein said anti-WISP-1 antibody is linked to one or more agents selected from the group consisting of non-proteinaceous polymer, cytotoxic agent, enzyme, radioisotope, fluorescent compound, and chemiluminescent compound.

58. (new) The hybridoma cell line which produces monoclonal antibody 3D11, 11C2, 9C10, 5D4, or 9C11 deposited with ATCC as accession number PTA-4624, PTA-4628, PTA-4626, PTA-4625, or PTA-4627, respectively.